

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2022-03-22** | Period of Report: **2022-03-21**
SEC Accession No. [0001157523-22-000358](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

CROSS COUNTRY HEALTHCARE INC

CIK: **1141103** | IRS No.: **134066229** | State of Incorporation: **DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **000-33169** | Film No.: **22760231**
SIC: **7363** Help supply services

Mailing Address

6551 PARK OF COMMERCE
BOULEVARD, N.W.
BOCA RATON FL 33487

Business Address

6551 PARK OF COMMERCE
BOULEVARD, N.W.
BOCA RATON FL 33487
8003472264

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 21, 2022



Cross Country Healthcare, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

0-33169
(Commission
File Number)

13-4066229
(I.R.S. Employer
Identification No.)

6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida 33487
(Address of Principal Executive Office) (Zip Code)

(561) 998-2232
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

**Name of each exchange on which
registered**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.01 Entry into a Material Definitive Agreement

On March 21, 2022, Cross Country Healthcare, Inc. (the "Company") amended its ABL Credit Agreement dated October 25, 2019, as amended, restated or otherwise modified from time to time, among the Company, substantially all of its wholly-owned subsidiaries, and Wells Fargo Bank N.A., as lender and administrative agent. The facility may be further syndicated at a later date. The amendment increases the current aggregate committed size of the asset-based credit facility from \$150 million to \$300 million, extends the credit facility for an additional five years, and increases certain borrowing base sub-limits. In addition, the agreement provides the option for all or a portion of the borrowings to bear interest at a rate based on SOFR or base rate, at the election of the borrowers, plus an applicable margin. The applicable margin will increase 10 basis points due to the credit spread associated with the transition to SOFR.

The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended ABL Credit Agreement as filed as Exhibit 10.1 to this Form 8-K.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The information provided in Item 1.01 of this Current Report on Form 8-K is incorporated into Item 2.03 by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit	Description
10.1	Amendment No. 5 to ABL Credit Agreement and Amendment No. 2 to Guaranty and Security Agreement, dated as of March 21, 2022, by and among Cross Country Healthcare, Inc. and certain of its domestic subsidiaries as borrowers or guarantors, and Wells Fargo Bank N.A., as administrative agent, collateral agent, and lender
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

CROSS COUNTRY HEALTHCARE, INC.

Dated: March 22, 2022

By: /s/ William J. Burns
William J. Burns
Executive Vice President & Chief Financial Officer

AMENDMENT NO. 5 TO ABL CREDIT AGREEMENT
AND AMENDMENT NO. 2 TO GUARANTY AND SECURITY AGREEMENT

AMENDMENT NO. 5 TO ABL CREDIT AGREEMENT AND AMENDMENT NO. 2 TO GUARANTY AND SECURITY AGREEMENT, dated as of March 21, 2022 (this “Amendment No. 5”), is by and among Wells Fargo Bank, National Association, a national banking association, as administrative agent for each member of the Lender Group and the Bank Product Providers (in such capacity, together with its successors and assigns in such capacity, “Agent”), Wells Fargo Bank, National Association, a national banking association, in its capacity as sole lead arranger (in such capacity, together with its successors and assigns in such capacity, the “Lead Arranger”), Wells Fargo Bank, National Association, a national banking association as sole book runner (in such capacity, together with their successors and assigns in such capacity, the “Book Runner”), Wells Fargo Bank, National Association, a national banking association, as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), Cross Country Healthcare, Inc., a Delaware corporation (“Parent”), Cejka Search, LLC, a Delaware limited liability company (“Cejka”), Cross Country Staffing, Inc., a Delaware corporation (“Cross Country Staffing”), Assignment America, LLC., a Delaware limited liability company (“Assignment America”), Travel Staff, LLC, a Delaware limited liability company (“Travel Staff”), Medical Doctor Associates, LLC, a Delaware limited liability company (“Medical Doctor”), OWS, LLC, a Delaware limited liability company (“OWS”), New Mediscan II, LLC, a California limited liability company (“New Mediscan” and together with Parent, Cejka, Cross Country Staffing, Assignment America, Travel Staff, Medical Doctor, OWS and those additional persons that hereafter become parties thereto as Borrowers in accordance with the terms thereof, each, a “Borrower” and individually and collectively, jointly and severally, the “Borrowers”), Cross Country Tech, LLC, a Delaware limited liability company (“Tech”), and Credent Verification and Licensing Services, LLC, a Delaware limited liability company (“Credent Verification” and together with Tech and those additional persons that hereafter become parties thereto as Guarantors in accordance with the terms thereof, each, a “Guarantor” and individually and collectively, jointly and severally, the “Guarantors”).

W I T N E S S E T H:

WHEREAS, Agent, Lenders, Borrowers and Guarantors have entered into senior secured asset-based revolving credit facility pursuant to which Lenders (or Agent on behalf of Lenders) have made and may make loans and advances and provide other financial accommodations to Borrowers as set forth in the ABL Credit Agreement, dated as of October 25, 2019, by and among Agent, Lenders, Borrowers and Guarantors, as amended by Amendment No. 1 to ABL Credit Agreement, dated as of June 30, 2020, by and among Agent, Lenders, Borrowers and Guarantors, Amendment No. 2 to ABL Credit Agreement and Amendment No. 1 to Guaranty and Security Agreement, dated as of March 8, 2021, by and among Agent, Lenders, Borrowers and Guarantors, Amendment No. 3 to ABL Credit Agreement, dated as of June 8, 2021, by and among Agent, Lenders, Borrowers and Guarantors and Amendment No. 4 to ABL Credit Agreement, dated as of November 18, 2021 (as the same is amended hereby and may from time to time hereafter be further amended, modified, supplemented, extended, renewed, restated or replaced, the “Credit Agreement”);

WHEREAS, Borrowers and Guarantors have requested that Agent and Lenders agree to certain amendments to the Credit Agreement and Security Agreement and Agent and Lenders are willing to agree to such amendments subject to the terms and conditions contained herein;

WHEREAS, Agent, Lenders, Borrowers and Guarantors intend to evidence such amendments pursuant to the terms hereof;

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements and covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. Definitions.

1.1. Additional Definitions. The Credit Agreement is hereby amended to include, in addition and not in limitation, the following definitions:

“Amendment No. 5” means Amendment No. 5 to ABL Credit Agreement, dated as of March 21, 2022, by and among Agent, Lenders, Borrowers and Guarantors, as the same now exists or may hereafter be amended, amended and restated, modified, supplemented, extended, renewed, restated or replaced.

“Amendment No. 5 Documents” has the meaning set forth in Section 5 of Amendment No. 5.

“Amendment No. 5 Effective Date” means the first date upon which each of the conditions set forth in Section 5 of Amendment No. 5 have been satisfied (or waived in writing).

“Amendment No. 5 Fee Letter” means the engagement fee letter, dated March 21, 2022, between Parent and Wells Fargo.

“Second Amendment to Intercreditor Agreement” means the Second Amendment to Intercreditor Agreement, dated as of March 21, 2022, by and among Administrative Agent and Term Loan Agent, as acknowledged and agreed to by Loan Parties, in form and substance reasonably satisfactory to Administrative Agent.

1.2. Interpretation. For purposes of this Amendment No. 5, all terms used herein which are not otherwise defined herein, including but not limited to, those terms used in the recitals hereto, shall have the respective meanings assigned thereto in the Credit Agreement.

2. Amendments to Credit Agreement.

2.1. The Credit Agreement is hereby amended by deleting the bold, stricken text (indicated textually in the same manner as the following example: ~~stricken text~~) and adding the bold, underlined text (indicated textually in the same manner as the following example: underlined text) as set forth in Exhibit A hereto. The amendments provided for in Exhibit A shall not, in any manner, be construed to impair, limit, cancel or extinguish, or constitute a novation in respect of, the Indebtedness and other obligations and liabilities of any Loan Party evidenced by or arising under the Credit Agreement or the other Loan Documents, and the liens and security interests securing such Indebtedness and other obligations and liabilities, which shall not in any manner be impaired, limited, terminated, waived or released but shall continue in full force and effect in favor of Agent and the Lender Group (as amended hereby). By executing this Amendment No. 5, the Loan Parties, Agent and Lenders (constituting all Lenders) hereby each consents and agrees to the other amendments and modifications to the Credit Agreement contained in Exhibit A to this Amendment No. 5.

2.2. Each of the Schedules to the Credit Agreement that are specified in Exhibit B hereto are hereby amended and restated in their entirety as set forth in Exhibit B hereto. All references to each of such Schedules to the Credit Agreement in the Credit Agreement or any other Loan Document are hereby amended to refer to the corresponding Schedule included as part of Exhibit B hereto. All other schedules to the Credit Agreement, as in effect immediately prior to the date of this Amendment No. 5, shall continue to constitute Schedules to the Credit Agreement. Exhibit S-1 to the Credit Agreement is hereby amended and restated in its entirety as set forth in Exhibit C hereto. All references to such Exhibit to the Credit Agreement in the Credit Agreement or any other Loan Document are hereby amended to refer to the Exhibit included as part of Exhibit C hereto. All other Exhibits to the Credit Agreement, as in effect immediately prior to the date of this Amendment No. 5, shall continue to constitute Exhibits to the Credit Agreement.

3. Amendments to Security Agreement.

3.1. Amendment to Definition-Cash Dominion Event. The definition of the term "Cash Dominion Event" in the Security Agreement is hereby deleted in its entirety and replaced with the following:

"Cash Dominion Event" means either (i) Excess Availability is less than the greater of (A) ten percent (10.0%) of the Loan Cap or (B) \$24,000,000, for at least five (5) consecutive Business Days or (ii) an Event of Default exists or has occurred and is continuing.

3.2. Amendment to Definition-Cash Dominion Period. The definition of the term "Cash Dominion Period" in the Security Agreement is hereby deleted in its entirety and replaced with the following:

"Cash Dominion Period" means the period commencing after the occurrence of a Cash Dominion Event and continuing until the date when (i) for a Cash Dominion Event triggered by clause (i) of the definition thereof, Excess Availability is equal to or greater than the greater of (A) ten percent (10.0%) of the Loan Cap and (B) \$24,000,000 for thirty (30) consecutive days and (ii) for a Cash Dominion Event triggered by clause (ii) of the definition thereof, the Event of Default giving rise to such Cash Dominion Event is cured or waived or otherwise no longer exists.

4. Representations and Warranties. Each Loan Party, jointly and severally, represents and warrants with and to Agent and Lenders as follows, which representations and warranties shall survive the execution and delivery hereof:

4.1. The execution, delivery and performance by each Loan Party of this Amendment No. 5 and the other Amendment No. 5 Documents (a) have been duly authorized by all necessary corporate or other organizational action, and (b) does not and will not (i) violate any material provision of federal, state, or local law or regulation applicable to any Loan Party or any of its Subsidiaries, the Organization Documents of any Loan Party or any of its Subsidiaries, or any order, judgment, or decree of any court or other Governmental Authority binding on any Loan Party or any of its Subsidiaries in each case in any material respect, (ii) conflict with, result in a breach of, or constitute (with due notice or lapse of time or both) a default under any material agreement of any Loan Party or any of its Subsidiaries where any such conflict, breach or default could individually or in the aggregate reasonably be expected to have a Material Adverse Effect, (iii) result in or require the creation or imposition of any Lien of any nature whatsoever upon any assets of any Loan Party, other than Permitted Liens, or (iv) require any approval of any holder of Equity Interests of a Loan Party or any approval or consent of any Person under any material agreement of any Loan Party, other than consents or approvals that have been obtained and that are still in force and effect and except, in the case of material agreements, for consents or approvals, the failure to obtain could not individually or in the aggregate reasonably be expected to have a Material Adverse Effect.

4.2. All of the representations and warranties of each Loan Party or its Subsidiaries contained in the Credit Agreement, the Security Agreement or any of the other Loan Documents are true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality or Material Adverse Effect (or words of similar import) in the text thereof) on and as of the date hereof, as though made on and as of such date (except to the extent that such representations and warranties relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality or Material Adverse Effect (or words of similar import in the text thereof) as of such earlier date).

4.3. The agreements and obligations of each Loan Party contained in this Amendment No. 5 and the other Amendment No. 5 Documents to which such Loan Party is a party constitute legal, valid and binding obligations of such Loan Party, enforceable against it in accordance with their terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors' rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law.

4.4. As of the Amendment No. 5 Effective Date, and after giving effect to this Amendment No. 5 and the other Amendment No. 5 Documents to be executed on or about the date hereof, no Default or Event of Default exists or has occurred and is continuing.

5. Conditions Precedent. This Amendment No. 5 shall be effective upon the satisfaction of each of the following conditions precedent:

5.1. Administrative Agent shall have received each of the following, each properly executed by an Authorized Person of the signing Loan Party or the Lenders, as applicable, each in form and substance satisfactory to Administrative Agent (collectively, the "Amendment No. 5 Documents"):

(a) this Amendment No. 5, duly authorized, executed and delivered by the Lenders and Loan Parties;

(b) the Second Amendment to the Intercreditor Agreement duly authorized, executed and delivered by the Term Loan Agent and Loan Parties;

5.2. Administrative Agent shall have received a certificate from the Secretary of each Loan Party (a) attesting to the resolutions of such Loan Party's board of directors or equivalent body authorizing its execution, delivery, and performance of the Loan Documents to which it is a party, (b) authorizing specific officers of such Loan Party to execute the same, and (c) attesting to the incumbency and signatures of such specific officers of such Loan Party;

5.3. Administrative Agent shall have received copies of each Loan Party's Organization Documents, as amended, modified, or supplemented to the Amendment No. 5 Effective Date, which Organization Documents shall be (a) certified by the Secretary or an Authorized Person of such Loan Party, and (b) with respect to Organization Documents that are charter documents, certified as of a recent date (not more than thirty (30) days prior to the Amendment No. 5 Effective Date) by the appropriate governmental official;

5.4. Administrative Agent shall have received a certificate of status with respect to each Loan Party, dated within thirty (30) days of the Amendment No. 5 Effective Date, such certificate to be issued by the appropriate officer of the jurisdiction of organization of such Loan Party, which certificate shall indicate that such Loan Party is in good standing in such jurisdiction;

5.5. Administrative Agent shall have received favorable opinions of counsel to the Loan Parties in form and substance reasonably satisfactory to Administrative Agent addressed to Administrative Agent and Lenders with respect to the Loan Parties, the Amendment No. 5 Documents and such other matters as Administrative Agent shall reasonably request (which such opinions shall expressly permit reliance by permitted successors and assigns of the addressees thereof);

5.6. the Excess Availability as of the Amendment No. 5 Effective Date, after provision for payment of all fees and expenses related to Amendment No. 5, shall be not less than \$100,000,000;

5.7. Administrative Agent shall have received a certificate signed by an Authorized Person of the Administrative Borrower certifying (i) that the conditions specified in this Section 5 have been satisfied, (ii) that there has been no event or circumstance since December 31, 2021 that has had or could reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect, (iii) that no Default or Event of Default exists or has occurred and is continuing, and (iv) either that (A) no consents, licenses or approvals are required in connection with the execution, delivery and performance by such Loan Party and the validity against such Loan Party of Amendment No. 5 and the other Amendment No. 5 Documents to which it is a party, or (B) that all such consents, licenses and approvals have been obtained as of the Amendment No. 5 Effective Date are in full force and effect;

5.8. Administrative Agent shall have received the FDPA compliance report required by its internal procedures with respect to Amendment No. 5;

5.9. Borrowers shall have paid in full all fees required to be paid to the Administrative Agent or the Lead Arranger, as applicable, pursuant to the Amendment No. 5 Fee Letter, on or before the Amendment No. 5 Effective Date;

5.10. Borrowers shall have paid all Lender Group Expenses incurred in connection with the transactions evidenced by Amendment No. 5, provided, that, for costs and expenses, invoices shall have been delivered to Administrative Borrower not less than one (1) Business Day prior to the Amendment No. 5 Effective Date; and

5.11. the Amendment No. 5 Effective Date shall have occurred on or before March 21, 2022.

6. Effect of Amendment No. 5. Except as expressly set forth herein and in prior amendments, no other amendments, changes or modifications to the Loan Documents are intended or implied, and in all other respects the Loan Documents are hereby specifically ratified, restated and confirmed by all parties hereto as of the effective date hereof and the Loan Parties shall not be entitled to any other or further amendment by virtue of the provisions of this Amendment No. 5 or with respect to the subject matter of this Amendment No. 5. To the extent of conflict between the terms of this Amendment No. 5 and the other Loan Documents, the terms of this Amendment No. 5 shall control. The Credit Agreement and this Amendment No. 5 shall be read and construed as one agreement. This Amendment No. 5 is a Loan Document. The Credit Agreement remains in full force and effect, and nothing contained in this Amendment No. 5 will constitute a waiver of any right, power or remedy under the Credit Agreement, the Security Agreement or any other Loan Document.

7. Governing Law. The validity, interpretation and enforcement of this Amendment No. 5 and any dispute arising out of the relationship between the parties hereto whether in contract, tort, equity or otherwise, shall be governed by the internal laws of the State of New York but excluding any principles of conflicts of law or other rule of law that would cause the application of the law of any jurisdiction other than the laws of the State of New York.

8. Jury Trial Waiver. LOAN PARTIES, AGENT AND LENDERS EACH HEREBY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS AMENDMENT NO. 5 OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AMENDMENT NO. 5 OR THE TRANSACTIONS RELATED HERETO OR THERETO IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE. LOAN PARTIES, AGENT AND LENDERS EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT EACH LOAN PARTY, AGENT OR LENDER MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AMENDMENT NO. 5 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

9. Binding Effect. This Amendment No. 5 shall be binding upon and inure to the benefit of each of the parties hereto and their respective successors and assigns.

10. Waiver, Modification, Etc. No provision or term of this Amendment No. 5 may be modified, altered, waived, discharged or terminated orally, but only by an instrument in writing executed by the party against whom such modification, alteration, waiver, discharge or termination is sought to be enforced.

11. Further Assurances. The Loan Parties shall execute and deliver such additional documents and take such additional action as may be reasonably requested by Agent to effectuate the provisions and purposes of this Amendment No. 5.

12. Entire Agreement. This Amendment No. 5, the Credit Agreement and the other Loan Documents represent the entire agreement and understanding concerning the subject matter hereof among the parties hereto, and supersedes all other prior agreements, understandings, negotiations and discussions, representations, warranties, commitments, proposals, offers and contracts concerning the subject matter hereof, whether oral or written.

13. Headings. The headings listed herein are for convenience only and do not constitute matters to be construed in interpreting this Amendment No. 5.

14. Counterparts. This Amendment No. 5, any documents executed in connection herewith and any notices delivered under this Amendment No. 5, may be executed by means of (i) an electronic signature that complies with the federal Electronic Signatures in Global and National Commerce Act, state enactments of the Uniform Electronic Transactions Act, or any other relevant and applicable electronic signatures law; (ii) an original manual signature; or (iii) a faxed, scanned, or photocopied manual signature. Each electronic signature or faxed, scanned, or photocopied manual signature shall for all purposes have the same validity, legal effect, and admissibility in evidence as an original manual signature. Agent reserves the right, in its sole discretion, to accept, deny, or condition acceptance of any electronic signature on this Amendment No. 5 or on any notice delivered to Agent under this Amendment No. 5. This Amendment No. 5 and any notices delivered under this Amendment No. 5 may be executed in any number of counterparts, each of which shall be deemed to be an original, but such counterparts shall, together, constitute only one instrument. Delivery of an executed counterpart of a signature page of this Amendment No. 5 and any notices as set forth herein will be as effective as delivery of a manually executed counterpart of this Amendment No. 5 or notice.

[remainder of page intentionally left blank]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 5 to be duly executed and delivered as of the day and year first above written.

BORROWERS:

CROSS COUNTRY HEALTHCARE, INC.

By: /s/ William Burns
Name: William Burns
Title: President & CFO

CEJKA SEARCH, LLC

By: /s/ William Burns
Name: William Burns
Title: Vice President

CROSS COUNTRY STAFFING, INC.

By: /s/ William Burns
Name: William Burns
Title: Vice President

ASSIGNMENT AMERICA, LLC.

By: /s/ William Burns
Name: William Burns
Title: Vice President

TRAVEL STAFF, LLC

By: /s/ William Burns
Name: William Burns
Title: Vice President

OWS, LLC

By: /s/ William Burns
Name: William Burns
Title: Vice President

[Signature Page to Amendment No. 5 to ABL Credit Agreement (Cross Country)]

NEW MEDISCAN II, LLC

By: /s/ William Burns

Name: William Burns

Title: Vice President

MEDICAL DOCTOR ASSOCIATES, LLC

By: /s/ William Burns

Name: William Burns

Title: Vice President

GUARANTORS:

CROSS COUNTRY TECH, LLC

By: /s/ William Burns

Name: William Burns

Title: Vice President

**CREDENT VERIFICATION AND LICENSING
SERVICES, LLC**

By: /s/ William Burns

Name: William Burns

Title: Vice President

[Signature Page to Amendment No. 5 to ABL Credit Agreement (Cross Country)]

WELLS FARGO BANK, NATIONAL ASSOCIATION,
a national banking association, as Administrative Agent,
Collateral Agent and as a Lender

By: /s/ Rina Shinoda

Name: Rina Shinoda

Title: Its Authorized Signatory

[Signature Page to Amendment No. 5 to ABL Credit Agreement (Cross Country)]

PNC BANK, NATIONAL ASSOCIATION, as a Lender

By: /s/ William Molyneux

Name: William Molyneux

Title: Its Authorized Signatory

[Signature Page to Amendment No. 5 to ABL Credit Agreement (Cross Country)]

EXHIBIT A
TO
AMENDMENT NO. 5 TO ABL CREDIT AGREEMENT
AND AMENDMENT NO. 2 TO GUARANTY AND SECURITY AGREEMENT

Amended Credit Agreement

See attached.

EXHIBIT B
TO
AMENDMENT NO. 5 TO ABL CREDIT AGREEMENT
AND AMENDMENT NO. 2 TO GUARANTY AND SECURITY AGREEMENT

Amended Schedules to Credit Agreement

See attached.

EXHIBIT C
TO
AMENDMENT NO. 5 TO ABL CREDIT AGREEMENT
AND AMENDMENT NO. 2 TO GUARANTY AND SECURITY AGREEMENT

Amended Exhibit S-1 to Credit Agreement

See attached.

**Document and Entity
Information**

Mar. 21, 2022

Cover [Abstract]

<u>Document Type</u>	8-K
<u>Amendment Flag</u>	false
<u>Document Period End Date</u>	Mar. 21, 2022
<u>Entity Registrant Name</u>	Cross Country Healthcare, Inc.
<u>Entity Incorporation, State or Country Code</u>	DE
<u>Entity File Number</u>	0-33169
<u>Entity Tax Identification Number</u>	13-4066229
<u>Entity Address, Address Line One</u>	6551 Park of Commerce Boulevard
<u>Entity Address, Address Line Two</u>	N.W.
<u>Entity Address, City or Town</u>	Boca Raton
<u>Entity Address, State or Province</u>	FL
<u>Entity Address, Postal Zip Code</u>	33487
<u>City Area Code</u>	561
<u>Local Phone Number</u>	998-2232
<u>Written Communications</u>	false
<u>Soliciting Material</u>	false
<u>Pre-commencement Tender Offer</u>	false
<u>Pre-commencement Issuer Tender Offer</u>	false
<u>Entity Emerging Growth Company</u>	false
<u>Entity Central Index Key</u>	0001141103
<u>Title of 12(b) Security</u>	Common stock, par value \$0.0001 per share
<u>Trading Symbol</u>	CCRN
<u>Security Exchange Name</u>	NASDAQ


```

"role": {
  "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form 8-I/A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
  "label": "Document Period End Date"
}
},
"localName": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdetype": "dateItemType"
},
"del_DocumentType": {
  "auth_ref": {},
  "lang": {},
  "ns-uri": {
    "role": {
      "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
    }
  }
},
"localName": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdetype": "submissionTypeItemType"
},
"del_EntityAddressAddressLine1": {
  "auth_ref": {},
  "lang": {},
  "ns-uri": {
    "role": {
      "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
      "label": "Entity Address, Address Line One"
    }
  }
},
"localName": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdetype": "normalizedStringItemType"
},
"del_EntityAddressAddressLine2": {
  "auth_ref": {},
  "lang": {},
  "ns-uri": {
    "role": {
      "documentation": "Address Line 2 such as Street or Suite number",
      "label": "Entity Address, Address Line Two"
    }
  }
},
"localName": "EntityAddressAddressLine2",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdetype": "normalizedStringItemType"
},
"del_EntityAddressAddressLine3": {
  "auth_ref": {},
  "lang": {},
  "ns-uri": {
    "role": {
      "documentation": "Address Line 3 such as an Office Park",
      "label": "Entity Address, Address Line Three"
    }
  }
},
"localName": "EntityAddressAddressLine3",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdetype": "normalizedStringItemType"
},
"del_EntityAddressCityOrTown": {
  "auth_ref": {},
  "lang": {},
  "ns-uri": {
    "role": {
      "documentation": "Name of the City or Town",
      "label": "Entity Address, City or Town"
    }
  }
},
"localName": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdetype": "normalizedStringItemType"
},
"del_EntityAddressCountry": {
  "auth_ref": {},
  "lang": {},
  "ns-uri": {
    "role": {
      "documentation": "ISO 3166-1 alpha-2 country code.",
      "label": "Entity Address, Country"
    }
  }
},
"localName": "EntityAddressCountry",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdetype": "countryCodeItemType"
},
"del_EntityAddressPostalZipCode": {
  "auth_ref": {},
  "lang": {},
  "ns-uri": {
    "role": {
      "documentation": "Code for the postal or zip code",
      "label": "Entity Address, Postal Zip Code"
    }
  }
},
"localName": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdetype": "normalizedStringItemType"
},
"del_EntityAddressStateOrProvince": {
  "auth_ref": {},
  "lang": {},
  "ns-uri": {
    "role": {
      "documentation": "Name of the state or province.",
      "label": "Entity Address, State or Province"
    }
  }
},
"localName": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdetype": "stateOrProvinceItemType"
},
"del_EntityCentralIndexKey": {
  "auth_ref": {
    "cik"
  },
  "lang": {},
  "ns-uri": {
    "role": {
      "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
      "label": "Entity Central Index Key"
    }
  }
},
"localName": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdetype": "centralIndexKeyItemType"
},
"del_EntityEmergingGrowthCompany": {
  "auth_ref": {
    "eic"
  },
  "lang": {},
  "ns-uri": {
    "role": {
      "documentation": "Indicate if registrant meets the emerging growth company criteria.",
      "label": "Entity Emerging Growth Company"
    }
  }
},
"localName": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdetype": "booleanItemType"
},
"del_EntityFileNumber": {
  "auth_ref": {},
  "lang": {},
  "ns-uri": {
    "role": {
      "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
      "label": "Entity File Number"
    }
  }
},
"localName": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdetype": "fileNumberItemType"
},
"del_EntityIncorporationStateCountryCode": {

```

```

"auth_ref": {},
"lang": {
  "en-us": {
    "role": {
      "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
      "label": "Entity Incorporation, State or Country Code"
    }
  }
},
"localName": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdrtType": "edgarStateCountryItemtype"
},
"del_EntityRegistrantName": {
  "auth_ref": {
    "is": {}
  },
  "lang": {
    "en-us": {
      "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
      }
    }
  }
},
"localName": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdrtType": "normalizedStringItemtype"
},
"del_EntityTaxIdentificationNumber": {
  "auth_ref": {
    "is": {}
  },
  "lang": {
    "en-us": {
      "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
      }
    }
  }
},
"localName": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdrtType": "employeeIdItemtype"
},
"del_LocalPhoneNumber": {
  "auth_ref": {
    "is": {}
  },
  "lang": {
    "en-us": {
      "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
      }
    }
  }
},
"localName": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdrtType": "normalizedStringItemtype"
},
"del_NoTradingSymbolFlag": {
  "auth_ref": {
    "is": {}
  },
  "lang": {
    "en-us": {
      "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
      }
    }
  }
},
"localName": "NoTradingSymbolFlag",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdrtType": "booleanItemtype"
},
"del_PreCommencementIssuerTenderOffer": {
  "auth_ref": {
    "is": {}
  },
  "lang": {
    "en-us": {
      "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
      }
    }
  }
},
"localName": "PreCommencementIssuerTenderOffer",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdrtType": "booleanItemtype"
},
"del_PreCommencementTenderOffer": {
  "auth_ref": {
    "is": {}
  },
  "lang": {
    "en-us": {
      "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
      }
    }
  }
},
"localName": "PreCommencementTenderOffer",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdrtType": "booleanItemtype"
},
"del_Security12bTitle": {
  "auth_ref": {
    "is": {}
  },
  "lang": {
    "en-us": {
      "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
      }
    }
  }
},
"localName": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdrtType": "securityTitleItemtype"
},
"del_SecurityExchangeName": {
  "auth_ref": {
    "is": {}
  },
  "lang": {
    "en-us": {
      "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
      }
    }
  }
},
"localName": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdrtType": "edgarExchangeCodeItemtype"
},
"del_SolicitingMaterial": {
  "auth_ref": {
    "is": {}
  },
  "lang": {
    "en-us": {
      "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 144-12 under the Exchange Act.",
        "label": "Soliciting Material"
      }
    }
  }
},
"localName": "SolicitingMaterial",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdrtType": "booleanItemtype"
},
"del_TradingSymbol": {
  "auth_ref": {
    "is": {}
  },
  "lang": {
    "en-us": {
      "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
      }
    }
  }
},
"localName": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dai/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"sdrtType": "tradingSymbolItemtype"
},
"del_WrittenCommunications": {
  "auth_ref": {
    "is": {}
  },
  "lang": {

```

```

"no-us": {
  "role": {
    "documentation": "Boolean flag that is true when the Form 9-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
    "label": "Written Communications"
  }
},
"localname": "WrittenCommunications",
"nsuri": "http://xbrl.sec.gov/9k/2021",
"presentation": {
  "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation"
},
"editype": "booleanItemType"
}
},
"unitCount": 0
},
"std_ref": {
  "id": {
    "Name": "Exchange Act",
    "Number": "240",
    "Publisher": "SEC",
    "Section": "12",
    "Subsection": "a"
  },
  "id": {
    "Name": "Exchange Act",
    "Number": "240",
    "Publisher": "SEC",
    "Section": "12",
    "Subsection": "a1"
  },
  "id": {
    "Name": "Exchange Act",
    "Number": "240",
    "Publisher": "SEC",
    "Section": "13a",
    "Subsection": "4c"
  },
  "id": {
    "Name": "Exchange Act",
    "Number": "240",
    "Publisher": "SEC",
    "Section": "14d",
    "Subsection": "2b"
  },
  "id": {
    "Name": "Exchange Act",
    "Number": "240",
    "Publisher": "SEC",
    "Section": "14",
    "Subsection": "12"
  },
  "id": {
    "Name": "Regulation 12B",
    "Number": "240",
    "Publisher": "SEC",
    "Section": "12",
    "Subsection": "b-2"
  },
  "id": {
    "Name": "Securities Act",
    "Number": "230",
    "Publisher": "SEC",
    "Section": "425"
  }
}
},
"version": "2.1"
}

```